Pfizer Voluntarily Withdraws Lipitor Advertising Featuring Dr. Robert Jarvik

PfizerPfizer said today that it is voluntarily withdrawing Lipitor advertising and promotion featuring Dr. Robert Jarvik and committing to ensuring greater clarity in the roles and responsibilities of its spokespeople in its consumer advertising and promotion.

Commenting on the withdrawal of the Jarvik advertising and promotion, Pfizer's President of Worldwide Pharmaceutical Operations Ian Read said: "The consumer advertising featuring Dr. Jarvik, a well-respected heart expert and inventor of the Jarvik artificial heart, provided valuable and medically accurate information about the risks of high cholesterol and how Lipitor can help patients reduce their risk of heart attack and stroke. Direct-to-consumer advertising is an important way to provide consumers with information about their health and treating disease, and at least 29 million Americans have talked to their physicians about a health condition for the first time after seeing a pharmaceutical advertisement.

"Nevertheless, the way in which we presented Dr. Jarvik in these ads has, unfortunately, led to misimpressions and distractions from our primary goal of encouraging patient and physician dialogue on the leading cause of death in the world - cardiovascular disease. We regret this. Going forward, we commit to ensuring there is greater clarity in our advertising regarding the presentation of spokespeople.

"Raising awareness of the dangers of cardiovascular disease in the U.S. remains an urgent public health priority. Only half of all Americans who have high LDL cholesterol are even diagnosed, and just half of those are being treated. Future Lipitor campaigns, to be launched in several weeks, will continue to stress the critical importance of patients talking to their doctors so they can make informed choices about their treatment options," he added.

The benefits of statins such as Lipitor in treating heart disease are validated in clinical guidelines including those from the National Institutes of Health National Cholesterol Education Program, the American Heart Association, the American College of Cardiology and the American Diabetes Association. Lipitor has an established safety profile across the full dose range which is based on more than 15 years of clinical trial experience and nearly 144 million patient-years of experience.

For additional product information, visit www.Lipitor.com.


Related YouTube Video:

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...

Pfizer and BioNTech choose lead mRNA vaccine candi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a singl...